Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
cyclophosphamide + docetaxel + pertuzumab + trastuzumab
- Development stage
- Unknown
- Lead developer
- Roche
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Administration
- Intravenous, Oral, Subcutaneous
01
Overview
This combination is used for the treatment of HER2-positive breast cancer. **Cyclophosphamide** is a chemotherapy drug that works by interfering with DNA replication. **Docetaxel** is another chemotherapy agent that disrupts microtubule function, preventing cell division. **Pertuzumab** and **trastuzumab** are monoclonal antibodies targeting the HER2 protein, which is overexpressed in some breast cancers. They work by binding to different parts of the HER2 protein, preventing its dimerization and signaling, thus inhibiting cancer cell growth.
02
Targets
ERBB2 (Erb-b2 receptor tyrosine kinase 2)DNAMicrotubule
Beyond the preview
Go deeper on cyclophosphamide + docetaxel + pertuzumab + trastuzumab.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on cyclophosphamide + docetaxel + pertuzumab + trastuzumab.